METASTATIC OROPHARYNGEAL SQUAMOUS CELL CARCINOMA
Clinical trials for METASTATIC OROPHARYNGEAL SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC OROPHARYNGEAL SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC OROPHARYNGEAL SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to tame tough head and neck cancers
Disease control OngoingThis study is testing whether combining an immunotherapy drug (cemiplimab) with two low-dose chemotherapy drugs works better for treating head and neck cancer that has returned or spread. It will involve about 46 patients whose cancer has come back or spread and who haven't had o…
Matched conditions: METASTATIC OROPHARYNGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Marcelo Bonomi • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New Two-Drug attack on tough head and neck cancers
Disease control OngoingThis study is testing if adding a new drug called ipatasertib to a standard immunotherapy (pembrolizumab) works better for controlling advanced head and neck cancer that has returned or spread. It will involve about 52 adults who have not yet received treatment for their advanced…
Matched conditions: METASTATIC OROPHARYNGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:37 UTC
-
Radiation boost tested to help immune system fight advanced head and neck cancer
Disease control OngoingThis study is for adults whose head and neck cancer has spread to a few other places in the body. It tests if adding a targeted course of radiation therapy to standard immunotherapy helps patients live longer than immunotherapy alone. About 290 participants will be randomly assig…
Matched conditions: METASTATIC OROPHARYNGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Mar 17, 2026 12:55 UTC